No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
60 – 89
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
108 (estimated)
Sponsor
VA Office of Research and Development · Federal
Who this trial is looking for
This trial is looking for older veterans with sleep apnea and chronic obstructive pulmonary disease (COPD). Participants will be studied to see how their conditions affect thinking and memory and whether treatment can improve these issues.
Are You a Good Fit for This Trial?
You may be able to join if
I have been diagnosed with obstructive sleep apnea
I have been diagnosed with moderate-to-severe COPD
I am at least 60 years old
I am male or female
You may not be able to join if
I have mild COPD
I have mild obstructive sleep apnea
I smoke currently
I am pregnant
I have unstable heart disease
I have a recent serious illness within the last 4 months
I cannot use a nasal or face mask
I have a life expectancy of less than 6 months
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Cognitive dysfunction in the aging Veteran population is a growing health concern in the Veterans Health System. It is not known whether OSA coexisting with COPD will enhance the risk for cognitive dysfunction. The investigators sought to investigate whether these two highly prevalent diseases, that often co-exist as the 'Overlap Syndrome', combine to enhance cognitive impairment in the elderly Ve…
Cognitive dysfunction in the aging Veteran population is a growing health concern in the Veterans Health System. It is not known whether OSA coexisting with COPD will enhance the risk for cognitive dysfunction. The investigators sought to investigate whether these two highly prevalent diseases, that often co-exist as the 'Overlap Syndrome', combine to enhance cognitive impairment in the elderly Veteran population. Thus, the investigators will study whether elderly patients with Overlap syndrome have increased cognitive deficits compared with OSA or COPD alone. Additionally, treatment of OSA with positive airway pressure (PAP) has been shown to improve neurocognitive function in moderate-to-severe OSA while cognitive decline in COPD may be reversible through treatment with long-term oxygen therapy. The investigators will also study whether treatment with positive airway pressure (PAP) and supplemental oxygen vs PAP alone will improve cognitive function and improve quality of life of elderly Veterans.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* OSA defined by the International classification of Sleep Disorders-322 diagnostic criteria with moderate-to-severe disease, i.e. apnea hypopnea index (AHI) 15\* per hour by polysomnography
* Moderate-to-severe COPD defined by GOLD 2 and 3 (Global Obstructive Lung Disease) 23 c…
Inclusion Criteria:
* OSA defined by the International classification of Sleep Disorders-322 diagnostic criteria with moderate-to-severe disease, i.e. apnea hypopnea index (AHI) 15\* per hour by polysomnography
* Moderate-to-severe COPD defined by GOLD 2 and 3 (Global Obstructive Lung Disease) 23 criteria with FEV1/FVC ratio \<70% and FEV1 \>30% and \<80% of predicted based on PFT done within the past 1 year and a past significant history (10 pack-years) of smoking
* Age 60 years
* Male or female gender
Exclusion Criteria:
* Mild COPD
* Mild OSA
* Overlap Syndrome with mild OSA plus mild COPD
* Central sleep apnea defined as central apnea index \>5 per hour
* Already on daytime oxygen or nighttime CPAP, NIPPV, oral appliance
* Current smokers
* Pregnant women
* Disorders of hypoventilation due to known neuromuscular or chest wall diseases\*\*
* Patients with significant restrictive lung disease on pulmonary function testing
* Recent admission for any acute illness within the prior 4 months
* Current psychiatric illness requiring sedating medications
* Use of hypnotics, anxiolytics, sedating antidepressants, anticonvulsants, sedating antihistamines, stimulants, or other medications likely to affect alertness or daytime functioning for Aim 3/4
* For Aim 3 and 4 only, existing depression as assessed by the PHQ (Patient Health Questionnaire)-9 (score \>10)
* History of learning disability
* Inability to sign consent
* Epworth sleepiness score 18 or a near-miss or prior automobile accident due to sleepiness within the past 12 months
* Patients with unstable heart disease, decompensated heart failure, ejection fraction\<45% or uncontrolled arrhythmias
* Patients unable to use either a nasal or face mask (e.g., facial trauma)
* Consumption of \> 2 alcoholic beverages per day or past history of excessive alcohol use
* Current use of illicit drugs
* Patients who have problems with vision or dexterity and hence, cannot use CPAP/NIPPV
* Life expectancy is less than 6 months
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.